Allurion Technologies announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian distributor with 30 years of experience in bariatric and obesity care. The collaboration will leverage ProSurg’s network of more than 300 hospitals and multidisciplinary teams of dietitians, bariatric surgeons, and endoscopic specialists to introduce Allurion’s swallowable balloon and GLP‑1 therapy combination to the Brazilian market.
Brazil has a high and growing obesity prevalence, with projections that by 2030 29.6% of adults will be obese. The partnership positions Allurion to tap into a market where demand for non‑surgical weight‑loss solutions is rising. ProSurg’s established relationships and distribution infrastructure will accelerate market penetration and provide a ready platform for Allurion’s program.
Allurion’s Smart Capsule is an investigational device in the United States but has cleared regulatory approval in other markets. The Brazilian rollout will pair the capsule with GLP‑1 therapy, aligning with a trend toward combination therapy that improves patient outcomes and offers a differentiated approach to obesity treatment.
Allurion has faced declining revenues and net losses in recent quarters. Q3 2025 revenue fell to $2.7 million from $5.4 million in Q3 2024, and the company posted a net loss of $11.88 million versus a $8.74 million profit in the same quarter a year earlier. The partnership is seen as a potential revenue driver, but financial terms are undisclosed and the company remains focused on cost discipline and restructuring.
Dr. Shantanu Gaur said the partnership “reflects our commitment to find partners globally who believe in our approach to obesity care” and that they look forward to “developing the Brazilian market and establishing a new standard of care.” ProSurg CEO Deluz Masselli added that the collaboration “shares our vision of providing comprehensive care for patients struggling with chronic diseases like obesity.”
Brazil’s weight‑loss market includes other non‑surgical options such as pharmacotherapy and lifestyle programs. Allurion’s combination therapy offers a differentiated approach, but the company must navigate regulatory, reimbursement, and market‑entry challenges. The partnership’s success will depend on effective integration of the program into ProSurg’s network and on securing reimbursement pathways.
The partnership marks a strategic step in Allurion’s global expansion strategy, aiming to capture a share of Brazil’s sizable obesity market. While the deal could open new revenue opportunities, the company’s recent financial performance underscores the need for disciplined execution and continued focus on cost management.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.